Browse News
Filter News
Found 718 articles
-
Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature
3/15/2023
The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice.
-
HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023
3/14/2023
HotSpot Therapeutics, Inc. today announced it will present two poster presentations on the company's CBL-B program at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, in Orlando, FL.
-
Gatehouse Bio Announces Upcoming Presentation at RNA Leaders Europe Congress
3/13/2023
Gatehouse Bio announced today that its Chief Executive Officer, David W. Salzman, PhD, will present at the upcoming RNA Leaders Europe Congress, in Basel, Switzerland on March 15, 2023 at 12:20PM CET.
-
Prime Medicine Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/9/2023
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
-
If biopharma-focused co-working spaces continue to catch on, they could expand job opportunities for those outside of the typical hot spots.
-
Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
3/7/2023
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
-
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
2/27/2023
Revolution Medicines, Inc. announced its financial results for the quarter and year ended December 31, 2022, and provided an update on corporate progress.
-
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
2/9/2023
AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022.
-
Record short videos to assess Parkinson's disease, NERVTEX's First-in-Class AI-based Movement Dysfunction Assessment Software medical device approved
2/1/2023
NERVTEX's MoDAS (Movement Dysfunction Assessment Software) system, which is a First-in-Class Artificial Intelligence/Machine Learning (AI/ML)- based Software as a Medical Device(SaMD) for the analysis of motor symptoms of Parkinson's disease and other movement disorders, has been approved by the China National Medical Products Administration, making it the first video-based AI-powered medical device for the assessment of movement disorders.
-
CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research
1/19/2023
Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc.
-
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
1/12/2023
Advaxis, Inc. today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center.
-
Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023
1/9/2023
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company highlights its expected milestones and strategic priorities for 2023.
-
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
1/9/2023
Prime Medicine, Inc. provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.
-
HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B
1/3/2023
HotSpot Therapeutics, Inc. today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for HST-1011, the Company's investigational small molecule allosteric inhibitor of casitas B-lineage lymphoma-B (CBL-B).
-
5G in Healthcare Market Size To Expand Around USD 459.71 Bn By 2030
12/23/2022
The global 5G in healthcare market size accounted for USD 48.25billion in 2022 and is expected to attain around USD 459.71 billion by 2030 with a noteworthy CAGR of 32.55% from 2022 to 2030.
-
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
12/19/2022
ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.
-
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
-
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
12/6/2022
AbbVie and HotSpot Therapeutics, Inc. today announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
-
SonoThera closed its Series A round of financing Monday, counting $60.75 million in earnings and will use these proceeds to advance its ultrasound-guided, non-viral gene therapy platform.
-
Pediatric Clinical Trials Market Size, Growth, Trends | Report 2022-2030
12/2/2022
As per new report study, the global pediatric clinical trials market was estimated at USD 14.6 billion in 2021 and it is expected to surpass around USD 23.7 billion by 2030, poised to grow at a CAGR of 5.53% from 2022 to 2030.